TY - JOUR
T1 - Proteomic approach toward personalized sarcoma treatment
T2 - Lessons from prognostic biomarker discovery in gastrointestinal stromal tumor
AU - Kondo, Tadashi
AU - Suehara, Yoshiyuki
AU - Kikuta, Kazutaka
AU - Kubota, Daisuke
AU - Tajima, Takashi
AU - Mukaihara, Kenta
AU - Ichikawa, Hiroshi
AU - Kawai, Akira
PY - 2013/1
Y1 - 2013/1
N2 - Sarcomas range from curable tumors to those causing death via metastasis and recurrence. Thus, there is an urgent need for biomarker identification in order to assess the degree of malignancy, predict prognosis, and evaluate possible therapies. Various proteomic approaches and different clinical materials have been used to this end, and candidate biomarkers have been reported for the different types of sarcomas. However, the sample size used in these biomarker studies was generally insufficient, and thus far, no biomarker has been proved useful in clinics. Given that sarcomas are rare, biomarker validation in this setting is more challenging than in other malignancies. In gastrointestinal stromal tumor, adjuvant therapy has proven to be effective. However, only 40% patients experience metastasis after curative surgery alone, and the rest of the patients may not need adjuvant therapy. Using a proteomic approach, we identified pfetin (potassium channel tetramerization domain containing 12, KCTD 12) as a novel prognostic biomarker for sarcoma, and immunohistochemically confirmed its clinical usefulness by a multiinstitutional validation study. Here, we describe our experience and discuss the critical points in the discovery of this biomarker.
AB - Sarcomas range from curable tumors to those causing death via metastasis and recurrence. Thus, there is an urgent need for biomarker identification in order to assess the degree of malignancy, predict prognosis, and evaluate possible therapies. Various proteomic approaches and different clinical materials have been used to this end, and candidate biomarkers have been reported for the different types of sarcomas. However, the sample size used in these biomarker studies was generally insufficient, and thus far, no biomarker has been proved useful in clinics. Given that sarcomas are rare, biomarker validation in this setting is more challenging than in other malignancies. In gastrointestinal stromal tumor, adjuvant therapy has proven to be effective. However, only 40% patients experience metastasis after curative surgery alone, and the rest of the patients may not need adjuvant therapy. Using a proteomic approach, we identified pfetin (potassium channel tetramerization domain containing 12, KCTD 12) as a novel prognostic biomarker for sarcoma, and immunohistochemically confirmed its clinical usefulness by a multiinstitutional validation study. Here, we describe our experience and discuss the critical points in the discovery of this biomarker.
KW - Biomarker
KW - Sarcoma
UR - http://www.scopus.com/inward/record.url?scp=84872711867&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872711867&partnerID=8YFLogxK
U2 - 10.1002/prca.201200085
DO - 10.1002/prca.201200085
M3 - Review article
C2 - 23281253
AN - SCOPUS:84872711867
VL - 7
SP - 70
EP - 78
JO - Proteomics - Clinical Applications
JF - Proteomics - Clinical Applications
SN - 1862-8346
IS - 1-2
ER -